Peter M Moyle

List of Publications by Year
in descending order

63	1,970	218677 26	254184 43
papers	citations	h-index	g-index

65	65	65	2430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modern Subunit Vaccines: Development, Components, and Research Opportunities. ChemMedChem, 2013, 8, 360-376.	3.2	347
2	Self-Adjuvanting Lipopeptide Vaccines. Current Medicinal Chemistry, 2008, 15, 506-516.	2.4	135
3	Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Biotechnology Advances, 2017, 35, 375-389.	11.7	76
4	Soil bacterial diffusible and volatile organic compounds inhibit Phytophthora capsici and promote plant growth. Science of the Total Environment, 2019, 692, 267-280.	8.0	67
5	Structureâ€"Activity Relationship of a Series of Synthetic Lipopeptide Self-Adjuvanting Group A Streptococcal Vaccine Candidates. Journal of Medicinal Chemistry, 2008, 51, 167-172.	6.4	65
6	Glucagonâ€Like Peptideâ€1 (GLPâ€1)â€Based Therapeutics: Current Status and Future Opportunities beyond Typeâ€...2 Diabetes. ChemMedChem, 2018, 13, 662-671.	3.2	62
7	Mucosal Immunisation: Adjuvants and Delivery Systems. Current Drug Delivery, 2004, 1, 385-396.	1.6	59
8	An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. MBio, 2019, 10, .	4.1	57
9	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Molecular Pharmaceutics, 2019, 16, 2278-2295.	4.6	54
10	Method for the Synthesis of Mono-ADP-ribose Conjugated Peptides. Journal of the American Chemical Society, 2010, 132, 15878-15880.	13.7	52
11	Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. MBio, 2016, 7, .	4.1	51
12	Modern lipidâ€, carbohydrateâ€, and peptideâ€based delivery systems for peptide, vaccine, and gene products. Medicinal Research Reviews, 2011, 31, 520-547.	10.5	47
13	Site-Specific Incorporation of Three Toll-Like Receptor 2 Targeting Adjuvants into Semisynthetic, Molecularly Defined Nanoparticles: Application to Group A Streptococcal Vaccines. Bioconjugate Chemistry, 2014, 25, 965-978.	3.6	46
14	Toward the Development of Prophylactic and Therapeutic Human Papillomavirus Type-16 Lipopeptide Vaccines. Journal of Medicinal Chemistry, 2007, 50, 4721-4727.	6.4	45
15	Polymerâ€"peptide hybrids as a highly immunogenic single-dose nanovaccine. Nanomedicine, 2014, 9, 35-43.	3.3	44
16	Endosome Escape Strategies for Improving the Efficacy of Oligonucleotide Delivery Systems. Current Medicinal Chemistry, 2015, 22, 3326-3346.	2.4	41
17	Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells. Acta Biomaterialia, 2017, 59, 257-268.	8.3	39
18	Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands. Bioconjugate Chemistry, 2018, 29, 572-586.	3.6	39

#	ARTICLE	IF	CITATIONS
19	Synthesis of a Highly Pure Lipid Core Peptide Based Self-Adjuvanting Triepitopic Group A Streptococcal Vaccine, and Subsequent Immunological Evaluation. Journal of Medicinal Chemistry, 2006, 49, 6364-6370.	6.4	38
20	Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. Nanomedicine, 2014, 9, 2613-2624.	3.3	38
21	Oral Vaccine Delivery â€" New Strategies and Technologies. Current Drug Delivery, 2009, 6, 347-358.	1.6	36
22	Development of a Liposaccharide-Based Delivery System and Its Application to the Design of Group A Streptococcal Vaccines. Journal of Medicinal Chemistry, 2008, 51, 1447-1452.	6.4	34
23	Sortase A (SrtA) inhibitors as an alternative treatment for superbug infections. Drug Discovery Today, 2021, 26, 2164-2172.	6.4	33
24	An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 935-944.	3.3	32
25	Method for the synthesis of highly pure vaccines using the lipid core peptide system. Journal of Peptide Science, 2006, 12, 800-807.	1.4	31
26	Optimized Methods for the Production and Bioconjugation of Site-Specific, Alkyne-Modified Glucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery Platforms Using Copper-Catalyzed Alkyneâ€"Azide Cycloaddition. Bioconjugate Chemistry, 2020, 31, 1820-1834.	3.6	28
27	The contribution of non-human primate models to the development of human vaccines. Discovery Medicine, 2014, 18, 313-22.	0.5	26
28	Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor. Bioorganic and Medicinal Chemistry, 2016, 24, 5834-5841.	3.0	24
29	Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines. Chemical Science, 2016, 7, 2308-2321.	7.4	24
30	Method for the Synthesis of Multi-EpitopicStreptococcuspyogenesLipopeptide Vaccines Using Native Chemical Ligation. Journal of Organic Chemistry, 2006, 71, 6846-6850.	3.2	23
31	Peptide-based targeted polymeric nanoparticles for siRNA delivery. Nanotechnology, 2019, 30, 415604.	2.6	21
32	Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine. Journal of Controlled Release, 2020, 317, 96-108.	9.9	21
33	Progress in Vaccine Development. Current Protocols in Microbiology, 2015, 36, 18.1.1-18.1.26.	6.5	18
34	Developing GLP-1 Conjugated Self-Assembling Nanofibers Using Copper-Catalyzed Alkyneâ€"Azide Cycloaddition and Evaluation of Their Biological Activity. Bioconjugate Chemistry, 2021, 32, 810-820.	3.6	17
35	A technique for the synthesis of highly-pure, mono-epitopic, multi-valent lipid core peptide vaccines. Tetrahedron Letters, 2007, 48, 4965-4967.	1.4	15
36	Advances in Targeted Gene Delivery. Current Drug Delivery, 2019, 16, 588-608.	1.6	15

#	Article	IF	Citations
37	Investigation toward multiâ€epitope vaccine candidates using native chemical ligation. Biopolymers, 2008, 90, 624-632.	2.4	14
38	Nanosized, peptide-based multicomponent DNA delivery systems: optimization of endosome escape activity. Nanomedicine, 2016, 11, 907-919.	3.3	14
39	Bombesin/oligoarginine fusion peptides for gastrin releasing peptide receptor (GRPR) targeted gene delivery. Bioorganic and Medicinal Chemistry, 2018, 26, 516-526.	3.0	14
40	Towards the Development of a Broadly Protective Group A Streptococcal Vaccine Based on the Lipid-Core Peptide System. Current Medicinal Chemistry, 2007, 14, 2976-2988.	2.4	13
41	Design and evaluation of a stearylated multicomponent peptide-siRNA nanocomplex for efficient cellular siRNA delivery. Nanomedicine, 2017, 12, 281-293.	3.3	12
42	Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. International Journal of Peptide Research and Therapeutics, 2003, 10, 605-613.	0.1	9
43	Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System. International Journal of Peptide Research and Therapeutics, 2006, 12, 317-326.	1.9	9
44	Preparation of albendazole-loaded liposomes by supercritical carbon dioxide processing. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, S1186-S1192.	2.8	9
45	Dispersibility of phospholipids and their optimization for the efficient production of liposomes using supercritical fluid technology. International Journal of Pharmaceutics, 2019, 563, 174-183.	5.2	9
46	Peptide based DNA nanocarriers incorporating a cell-penetrating peptide derived from neurturin protein and poly-l-lysine dendrons. Bioorganic and Medicinal Chemistry, 2015, 23, 2470-2479.	3.0	8
47	Gastrin-releasing peptide receptor-targeted hybrid peptide/phospholipid pDNA/siRNA delivery systems. Nanomedicine, 2019, 14, 1153-1171.	3.3	8
48	Formulation and Biological Evaluation of Mesoporous Silica Nanoparticles Loaded with Combinations of Sortase A Inhibitors and Antimicrobial Peptides. Pharmaceutics, 2022, 14, 986.	4.5	8
49	Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5570-5575.	2.2	6
50	Peptide-Based Multicomponent Oligonucleotide Delivery Systems: Optimisation of Poly-l-lysine Dendrons for Plasmid DNA Delivery. International Journal of Peptide Research and Therapeutics, 2017, 23, 119-134.	1.9	6
51	Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Toward a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoproteinâ€"Fusion Combination Vaccine. ACS Infectious Diseases, 2020, 6, 1770-1782.	3.8	6
52	Neutralisation of adeno-associated virus transduction by human vitreous humour. Gene Therapy, 2021, 28, 242-255.	4.5	6
53	Synthesis and Characterization of Luteinizing Hormone-Releasing Hormone (LHRH)-Functionalized Mini-Dendrimers. International Journal of Organic Chemistry, 2013, 03, 51-57.	0.7	5
54	A Selfâ€Adjuvanting Vaccine Platform: Optimization of Siteâ€Specific Sortase A Mediated Conjugation of Tollâ€Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein Antigens. ChemPlusChem, 2020, 85, 227-236.	2.8	5

#	Article	IF	Citations
55	Supercritical fluid assembly of albendazole liposomes targeting gastrin-releasing peptide receptor overexpressing tumors. Nanomedicine, 2020, 15, 1315-1330.	3.3	3
56	Optimized protocols for assessing libraries of poorly soluble sortase A inhibitors for antibacterial activity against medically-relevant bacteria, toxicity and enzyme inhibition. Bioorganic and Medicinal Chemistry, 2021, 52, 116527.	3.0	3
57	Towards the synthesis of a highly pure, multiepitopic, mucosal group A streptococcal lipopeptide vaccine. International Congress Series, 2006, 1289, 324-328.	0.2	1
58	YYâ€•11, a camel milkâ€•derived peptide, inhibits TGFâ€•Î²â€•mediated atherogenic signaling in human vascular smooth muscle cells. Journal of Food Biochemistry, 2022, 46, e13882.	2.9	1
59	The lipid core peptide system in vaccine delivery. International Congress Series, 2006, 1289, 307-310.	0.2	0
60	Development of Peptide Vaccines against HPV-16 Associated Cervical Cancer and Group A Streptococci. , 2006, , 407-408.		0
61	Vaccine Delivery: Synthesis and Investigation of a Highly Pure, Multi-Epitopic Lipopeptide Vaccine Candidate. Advances in Experimental Medicine and Biology, 2009, 611, 347-349.	1.6	0
62	Strategies in Oral Immunization. , 2009, , 195-222.		0
63	Vaccine delivery utilizing liposaccharides. Advances in Experimental Medicine and Biology, 2009, 611, 345-346.	1.6	0